drugset / Trial / NCT06826092
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
RandomizedParallel-groupOpen-labelSupportive care
Summary
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
Timeline
- Start
- 2022-10-31
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | — |
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | — |
| Comparator | Leucovorin | Small molecule | 200 mg/m2 | — |
| Comparator | fluorouracil | Small molecule | 2800 mg/m2 | — |
Indications
No indication recorded.